On August 27th, BeiGene announced that the US Food and Drug Administration (FDA) has granted the company BGB-16673 fast track designation for the treatment of adult patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously received at least two lines of treatment, including BTK inhibitors and BCL2 inhibitors.
It is reported that BGB-16673 is an orally administered, BTK targeted chimeric degradation activating compound (CDAC) under development. At present, the BGB-16673 global clinical development project has treated over 300 patients in 15 countries/regions. (He Xinyi)